BIOG-B 📈 BioGaia AB (publ) - Overview

BioGaia AB (publ) is a global healthcare company that specializes in the development and distribution of probiotic products, which are live microorganisms that provide health benefits when consumed. The company's product portfolio is divided into three main segments: Pediatrics, Adult Health, and Other. The Pediatrics segment focuses on providing probiotic solutions for infants and children, including drops, oral rehydration solutions, and gut health tablets, as well as cultures used in infant formula. This segment is critical in supporting the health and development of young children, particularly in terms of gut health and immune system development.

The Adult Health segment, on the other hand, caters to the health needs of adults, offering gut health tablets and oral health lozenges, as well as cultures used as ingredients in dairy products. This segment recognizes the importance of maintaining a healthy gut microbiome throughout adulthood, which can have a significant impact on overall health and wellbeing. By providing these products, BioGaia AB (publ) aims to support adults in managing their health and preventing certain diseases. The company's products are sold through a combination of distribution partners and its own distribution channels, allowing it to reach a wide range of customers globally.

In addition to its core probiotic products, BioGaia AB (publ) also operates an Other segment, which provides packaging solutions. This segment supports the company's overall operations by ensuring that its products are properly packaged and distributed to customers. With a history dating back to 1990, BioGaia AB (publ) has established itself as a leading player in the probiotic industry, with a strong presence in the global market. The company is headquartered in Stockholm, Sweden, and its common stock is listed under the ISIN code SE0017769995, classified under the Biotechnology sub-industry.